Trials / Completed
CompletedNCT02933710
Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
Postmarketing Surveillance Study for a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Republic of Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- 12 Months
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to perform the re-examination of IMOJEV® in routine clinical settings in accordance with the Ministry of Food and Drug Safety regulation. Primary objective: * To describe the safety profile of the first dose of IMOJEV® administered under routine health care visit as primary vaccination or as booster.
Detailed description
Subjects aged 12 months of age and older and who are given study vaccine during routine health-care visits will be enrolled in the study. No study vaccine will be supplied or administered as part of this study, subjects will be monitored following routine vaccine administration in clinical settings.
Conditions
Timeline
- Start date
- 2016-07-21
- Primary completion
- 2018-10-18
- Completion
- 2018-10-18
- First posted
- 2016-10-14
- Last updated
- 2022-04-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02933710. Inclusion in this directory is not an endorsement.